News of the WeekDRUG RESEARCH

Novartis Sows Its Future in U.S. Soil

See allHide authors and affiliations

Science  17 May 2002:
Vol. 296, Issue 5571, pp. 1216-1217
DOI: 10.1126/science.296.5571.1216

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

CAMBRIDGE, MASSACHUSETTS-- The Swiss drug giant Novartis, based in Basel, intends to set up a $250 million research facility here that will guide its overall R&D efforts--a move that has sent shock waves rippling through the company's home turf. Novartis's move is the latest blow to homegrown European drug research and reflects the company's efforts to keep U.S. competitors in its sights.